Symposium

NMOSD Unveiled: Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Launch Date
05/29/2024 at 5:00 pm EST
Credit Amount
1.5
Credit Expires
07/29/2024

Faculty

Rosemarie Walch, DO
Neuroimmunologist
Memorial Healthcare
Owosso, MI
Marijean Buhse, PhD, NP-BC, MSCN, FAAN
Nurse Practitioner
NYU South Shore Neurologic Associates
Islip, NY
Flavia Nelson, MD
Thomas F. Whigham-Joseph Berger, Chair in Neuroimmunology
Professor of Neurology
Chief, CNS Autoimmune Disorders Division
Director, Multiple Sclerosis Center of Excellence
University of Miami Leonard M. Miller School of Medicine
Miami, FL
Flavia Nelson, MD

Thomas F. Whigham-Joseph Berger, Chair in Neuroimmunology
Professor of Neurology
Chief, CNS Autoimmune Disorders Division
Director, Multiple Sclerosis Center of Excellence
University of Miami Leonard M. Miller School of Medicine
Miami, FL

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Neuromyelitis optica spectrum disorder (NMOSD) is a relatively new term for a group of rare, demyelinating autoimmune diseases affecting the central nervous system (CNS), particularly the optic nerves and spinal cord. In the past, NMOSD was conflated with multiple sclerosis (MS) due to significant similarities in early-stage presentation. However, recent evidence has shown NMOSD to be a unique disorder with an antibody-mediated etiology distinct from MS. Without proper diagnosis and treatment, patients with NMOSD are likely to develop significant and progressive disability with each recurrent attack.

Due to the relatively recent recognition of NMOSD as a distinct diagnostic entity, health care practitioners (HCPs) may lack knowledge and familiarity in its optimal diagnosis and management. It is essential that HCPs understand the etiology and pathophysiology of NMOSD, how novel therapies work to prevent NMOSD attacks, and long-term management strategies that can be utilized in clinical practice.

In this CME Outfitters’ live symposium, expert faculty will discuss strategies to better identify the pathological hallmarks of NMOSD, evaluate diagnostic criteria, utilize established and emerging therapeutics, and implement ongoing care of patients with NMOSD.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the pathophysiology of NMOSD including the role of the complement mechanism in the disease state
  • Evaluate diagnostic criteria including clinical presentation, AQP4-IgG status, and magnetic resonance imaging (MRI) findings to accurately diagnose NMOSD
  • Utilize recently approved and emerging NMOSD therapeutic antibodies in preventing acute episodes, associated damage, and long-term disability
  • Implement ongoing care and monitoring of patients with NMOSD to optimize long-term outcomes

Financial Support

Supported by an educational grant from Alexion Pharmaceuticals.

Target Audience

Adult neuroimmunologists, neuroradiologists, neurologists, internists, and ancillary HCPs – physician associates (PAs),  nurse practitioners (NPs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.50 contact hours ( 0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-034-L01-P).

PAs (AAPA) 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 07/29/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Walch reports the following financial relationships:

Advisory Board: Alexion Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Genentech, Inc./Roche; Genzyme Corporation; and Sanofi

Consultant: Alexion Pharmaceuticals, Inc.; Amgen Inc./Horizon Therapeutics; and TG Therapeutics, Inc.

Grants: CMSC Foundation

Research Support: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Biogen; EMD Serono; Genentech, Inc./Roche; Novartis. Pharmaceuticals Corporation; Roche; Sanofi; and TG Therapeutics, Inc.

Speakers Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc./Horizon Therapeutics, Inc.; and Biogen

Dr. Buhse reports no financial relationships to disclose.

Dr. Nelson reports the following financial relationships:

Advisory Board: Genentech, Inc. and Horizon Therapeutics

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Evan Luberger (Planning Committee)
Kellie Busby, PharmD, BCPP (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MM-144-052924-87

NMOSD Unveiled: Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies
Event Date: 05/29/2024 at 5:00 pm EST
Register